Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors - Related Studies

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

This study is currently recruiting participants.

Study NCT00703638. Last updated on September 22, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Breast Cancer
		Colorectal Cancer
		Head and Neck Cancer
		Lung Cancer
		Malignant Mesothelioma
		Pancreatic Cancer
		Prostate Cancer
		Sarcoma

2	Additional conditions recognized in this trial
		Breast Neoplasms
		Colorectal Neoplasms
		Head and Neck Neoplasms
		Lung Neoplasms
		Mesothelioma
		Pancreatic Neoplasms
		Prostatic Neoplasms

3	More general conditions related to this trial
		Adenoma
		Breast Diseases
		Colonic Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Genital Diseases, Male
		Genital Neoplasms, Male
		Intestinal Diseases
		Intestinal Neoplasms
		Lung Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Connective and Soft Tissue
		Neoplasms, Glandular and Epithelial
		Neoplasms, Mesothelial
		Pancreatic Diseases
		Prostatic Diseases
		Rectal Diseases
		Respiratory Tract Diseases
		Respiratory Tract Neoplasms
		Skin Diseases
		Thoracic Neoplasms
		Urogenital Neoplasms

4	Interventions listed in this trial
		cisplatin
		pemetrexed disodium
		sorafenib tosylate

5	Additional drug interventions recognized in this trial
		Pemetrexed
		Sorafenib

6	More general drug interventions related to this trial
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Enzyme Inhibitors
		Folic Acid Antagonists
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protein Kinase Inhibitors
		Radiation-Sensitizing Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Masonic Cancer Center, University of Minnesota
		National Cancer Institute (NCI)